A U.S. court unsealed documents showing Abacus Global Management relied on inaccurate, short life expectancy estimates from Lapetus Solutions, misleading investors about the value of life settlement policies. The evidence reveals Lapetus had an actual-to-expected death ratio of only 41.5%, far below industry norms near 100%, indicating systematic underestimation of life spans. Abacus also misrepresented a valuation report from Lewis & Ellis by using selective discount rates and withholding longer life expectancy estimates, inflating policy values. Coventry First LLC, the plaintiff, has refiled counterclaims with this new evidence and continues to seek full disclosure, highlighting risks to investors including credit unions with over $500 million invested.
Kimberly-Clark reported Q2 earnings per share of $1.80, missing the expected $2.01, and revenue of $4.19 billion, slightly below the $4.22 billion forecast. The company lowered its growth expectations due to cautious consumer spending, a fire at a di...
Amgen is set to report its Q2 2026 earnings with analysts forecasting a 2.9% increase in revenue to about $9.45 billion, despite a projected 7% drop in earnings to $5.60 per share. The company benefits from strong sales of key drugs like Repatha, Tez...
Kaltura introduced real-time emotional intelligence for its AI Agentic Avatars, enabling them to interpret user tone and conversational intent instantly. This technology allows avatars to respond with synchronized facial expressions and vocal nuances...
Gartner reported strong Q2 2026 results, with earnings per share (EPS) of $4.37, surpassing analyst expectations of $3.76 and showing over 15% earnings surprise. Revenue reached $1.68 billion, slightly above estimates but down from $1.69 billion a ye...
PROCEPT BioRobotics is confronting a securities fraud class action lawsuit alleging it artificially boosted sales by pulling future sales into current quarters. This legal issue caused an 18% drop in its stock price. The company is set to report earn...
